If anti-obesity medications were to be approved for OSA treatment, clinicians would need to be aware that its vital to primarily address proper nutrition, tolerable physical activity, and identification of weight-modifying behaviors while using anti-obesity medications as complementary tools to treat obesity, Dr
During these times, the FDA allowed compounding pharmacies to produce semaglutide to ensure patients didnt have to stop their treatment abruptly
She didnt know it was banned and instead, she got banned
From a commercial perspective, the shift toward chronic weight management as a reimbursable healthcare goal is unlocking new patient populations, payer models, and regulatory pathways
When a cancer patient can buy a 30-day supply of imatinib for $13.40 at Cost Plus instead of paying $2,500 at a retail chain, the patent defense that Novartis spent years constructing around that molecule stops mattering to that patient [1]
A doctor might prescribe them Ozempic or a similar drug because they have a higher BMI, with the assumption that using the drug to lose weight would make that person healthier